Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
08/27/14Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating, Double-Stranded Molecules of 19 to 52 Nucleotides in Length
– Allowed Claims of Tuschl ’829 Application Broadly Cover Small Interfering RNA Molecules, Including “Dicer Substrate” Designs – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 27, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl et al. patent application 12/591,829. The ’829 paten... 
Printer Friendly Version
08/20/14Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating Double-Stranded Molecules Comprising Up to 25 Base Pairs
– Allowed Claims of Tuschl ’262 Application Broadly Cover “Dicer Substrate” and Other RNAi Molecules, Including Those Containing Nucleotide Analogs such as “Unlocked Nucleobase Analogs (UNAs)” – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims... 
Printer Friendly Version
08/07/14Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 7, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targ... 
Printer Friendly Version
08/07/14Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities
– Achieved Positive Initial Results in Ongoing Phase 2 Open-Label Extension (OLE) Study with Patisiran, Showing Sustained Clinical Activity with Transthyretin (TTR) Knockdown at an 80% Target Level and Tolerability with Extended Dosing – – Reported Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, Demonstrating Statistically Significant Knockdown of Antithrombin (AT) and Increase in Thrombin Generation – – Br... 
Printer Friendly Version
07/31/14Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 31, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2014 on Thursday, August 7, 2014, after the U.S. financial markets close. Management will provide an update on the company, discuss second quarter 2014 results, and discuss expectations for the future via conference ... 
Printer Friendly Version
07/29/14Alnylam to Host Additional Events in “RNAi Roundtable” Webcast Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 29, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online “RNAi Roundtables” that it is hosting during July and August. Each event will be webcast live on the Investors section of the company’s website, www.alnylam.com. An audio replay of the roundtables will be posted on the Alnylam website ... 
Printer Friendly Version
07/22/14Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
– Allowed Claims of Manoharan ’478 Application Cover GalNAc-Conjugates Independent of Length, Sequence, and Disease Target – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 22, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478. The ’478 paten... 
Printer Friendly Version
07/07/14Alnylam to Host “RNAi Roundtable” Webcast Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online “RNAi Roundtables” during July and August. Alnylam scientists and key clinical collaborators will review recent progress from several of the “Alnylam 5x15” programs and discuss the related disease areas. Each event will be webcast live on the ... 
Printer Friendly Version
07/02/14Alnylam Elects Amy Schulman to its Board of Directors
– Appointment of Industry Leader Brings Broad Strategic, Commercial, and Legal Experience to Board – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 2, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pf... 
Printer Friendly Version
06/30/14Alnylam Added to Russell 1000 Index as a Member of the Large-Cap Segment of the U.S. Equity Universe
CAMBRIDGE, Mass., Jun 30, 2014 (BUSINESS WIRE) --Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014. The Russell 1000 Index measures the performance of the large-cap segment of the U.S. equity universe. It is a subset of the Russell 3000 Index and includes approximately 1000 of the largest securities based on a combinatio... 
Printer Friendly Version
06/19/14Alnylam and The Alpha-1 Project (TAP) Form Collaboration for Advancement of ALN-AAT, an RNAi Therapeutic in Development for the Treatment of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease
– Alnylam Remains On Track to File Investigational New Drug (IND) Application in Mid-2015 – CAMBRIDGE, Mass. & MIAMI--(BUSINESS WIRE)--Jun. 19, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, announced today that they have entered into a collaboration agreement for the continued advancement of ALN-A... 
Printer Friendly Version
06/17/14Alnylam to Webcast Presentation at 9th Annual JMP Securities Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24, 2014 at 10:30 a.m. ET at the Westin New York Grand Central in New York City. A live audio webcast of the presentation will be available on the Investors section o... 
Printer Friendly Version
06/12/14Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
– New ’277 McSwiggen Patent Includes Broad, Sequence-Independent Claims for Chemically Modified siRNAs Targeting the HBV Genome – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or “’277 patent”) in the company’s McSwiggen patent estat... 
Printer Friendly Version
06/09/14Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
– ALN-CC5 Demonstrates Potent C5 Knockdown of up to 98.7% and Inhibition of Complement Activity of up to 96.8% in Non-Human Primates (NHP) – – RNAi-Mediated Knockdown of C5 Shown to be as Effective as Anti-C5 Monoclonal Antibody in Reducing Clinical Disease Activity in Mouse Arthritis Model – – Company On Track to File Investigational New Drug (IND) Application in Late 2014 and Now Guides to Report Initial Clinical Results in ... 
Printer Friendly Version
06/04/14Alnylam to Webcast Presentation at Goldman Sachs 35th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014 at 10:40 a.m. PT (1:40 p.m. ET) at the Terranea Resort in Rancho Palos Verdes, Calif. A live audio webcast of the presentation will be available on the ... 
Printer Friendly Version
05/21/14Alnylam and Collaborators Publish Pre-Clinical Results with ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias, in the Proceedings of the National Academy of Sciences
– New Paper Documents Previously Presented Proof-of-Concept Results in Mouse Model of Acute Intermittent Porphyria (AIP) – – RNAi Therapeutics Targeting ALAS-1 Completely Block Production of Toxic Heme Biosynthesis Intermediates that Cause Symptoms and Disease Pathology – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the public... 
Printer Friendly Version
05/13/14Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
– Single, Lowest Dose Group of ALN-AT3 Achieves Statistically Significant Knockdown of AT and Increase in Thrombin Generation in “Part A” of Phase 1 Study in Normal Human Volunteers – – Results Demonstrate a Greater than 50-Fold Potency Improvement for Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates in Humans, Representing an Unprecedented Advance in Delivery of RNAi Therapeutics with Subcutaneous Dose Administration – ... 
Printer Friendly Version
05/12/14Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees
– New ALN-HBV Program Stems from Alnylam’s Acquisition of Sirna Therapeutics from Merck – – Alnylam Expects to Nominate ALN-HBV Development Candidate (DC) with Enhanced Stabilization Chemistry (ESC)-GalNAc-Conjugate Delivery Platform by End of 2014; File Investigational New Drug Application (IND) around Year-End 2015 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi t... 
Printer Friendly Version
05/11/14Alnylam Presents Key Scientific Data on Enhanced Stabilization Chemistry (ESC)-GalNAc-Conjugate Technology
– ESC-GalNAc-Conjugate Platform Enables Subcutaneous Delivery of RNAi Therapeutics with Increased Potency and Durability, and a Wide Therapeutic Index – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it is presenting key scientific data on its Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform. Specifically, t... 
Printer Friendly Version
05/08/14Alnylam Pharmaceuticals Reports First Quarter 2014 Financial Results and Highlights Recent Period Activities
– Formed Transformational Alliance with Genzyme for RNAi Therapeutics as Genetic Medicines; Acquired Merck RNAi Assets, Including Sirna Therapeutics Subsidiary – – Achieved Positive Initial Results from Phase 2 Open-Label Extension (OLE) Study with Patisiran, Showing Sustained Clinical Activity with Transthyretin (TTR) Knockdown at an 80% Target Level and Tolerability with Extended Dosing – – Initiated Phase 1 Study of ALN-AT3, an ... 
Printer Friendly Version
05/07/14Alnylam to Webcast Presentation at Bank of America Merrill Lynch 2014 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 at 9:20 a.m. PT (12:20 p.m. ET) at Encore at Wynn in Las Vegas. A live audio webcast of the presentation will be available on the Investors section o... 
Printer Friendly Version
05/06/14Alnylam Advances Development Candidate for ALN-AAT, a Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) in Development for the Treatment of AAT Deficiency-Associated Liver Disease
– Company Plans to File Investigational New Drug (IND) Application in mid-2015, Positioning ALN-AAT as the Seventh Clinical Program as Part of the Company’s Up-Scaled “Alnylam 5x15” Guidance – CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate (DC) for ALN-AAT, an RNAi therapeutic targeting alpha-1 ant... 
Printer Friendly Version
05/01/14Alnylam to Webcast Conference Call Discussing First Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter ending March 31, 2014 on Thursday, May 8, 2014, after the U.S. financial markets close. Management will provide an update on the company, discuss first quarter 2014 results, and discuss expectations for the future via conference ... 
Printer Friendly Version
05/01/14Alnylam Presents New Pre-clinical Data on Subcutaneously Delivered RNAi Therapeutics for Cardiovascular Metabolic Disease at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions
– Demonstrates Robust, Durable, and Clamped Knockdown of PCSK9 of up to 96% and Reduction of LDL-C of up to 77% with Single Dose of ALN-PCSsc in Absence of Statins in Non-Human Primates – – Data Support Once-Monthly and Possibly Once-Quarterly Subcutaneous Dosing Regimen with an RNAi Therapeutic for the Treatment of Hypercholesterolemia – – Broadens Pipeline with ALN-AC3, a Subcutaneously Administered RNAi Therapeutic Targeting Apo... 
Printer Friendly Version
04/30/14Alnylam to Webcast Presentation at Deutsche Bank 39th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 30, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 2:10 p.m. ET at The InterContinental Hotel in Boston. A live audio webcast of the presentation will be available on the Investors section of the company’... 
Printer Friendly Version
04/29/14Alnylam Presents New Pre-clinical Data on RNAi Therapeutics Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)
– TTR Knockdown Shown to be Highly Correlated with Regression of TTR Deposits in Mouse Disease Model – – Comparative Studies Exhibit Superior Activity of RNAi Over Stabilizers Toward Regression of TTR Deposits in Mouse Disease Model – – Comparative Studies Establish Greater TTR Knockdown with Over 100-Fold Lower Tissue Exposure for RNAi Therapeutics versus Antisense Oligonucleotides (ASO) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ap... 
Printer Friendly Version
04/28/14Alnylam and Collaborators Present New Clinical Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR)
– Company Presents Positive Initial Data from Phase 2 Open-Label Extension (OLE) Study, Showing Sustained Clinical Activity with TTR Knockdown at the 80% Target Level and Tolerability with Extended Dosing – – Company Also Presents Results of Natural History Study of ATTR Patients with Familial Amyloidotic Polyneuropathy (FAP), Showing Rapid Progression of Neuropathy Impairment Score and Correlation with Disease Severity – CAMBRIDGE, Ma... 
Printer Friendly Version
04/07/14Alnylam’s McSwiggen Patent Upheld in European Opposition Proceedings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 7, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld the McSwiggen EP 1423406 (’406) patent in oral opposition proceedings in Munich, Germany. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics that the company believes are critical for achieving “drug-like” propertie... 
Printer Friendly Version
04/02/14Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR). “We are very pleased to have ... 
Printer Friendly Version
04/02/14Alnylam to Webcast Presentation at 13th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 12:50 p.m. ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the co... 
Printer Friendly Version
03/26/14Genzyme Exercises its Right to Purchase Additional Shares of Alnylam Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 26, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Genzyme, a Sanofi company, has exercised its right to purchase 344,448 unregistered shares of Alnylam’s common stock in accordance with the terms of an investor rights agreement between Alnylam and Genzyme, dated January 11, 2014. These shares became available for purchase by Genzyme as a result... 
Printer Friendly Version
03/21/14Alnylam to Present Data from its RNAi Therapeutic Programs Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) at XIVth International Symposium on Amyloidosis (ISA)
– Presentations Include Results of 283-Patient Natural History Study of ATTR Patients with Familial Amyloidotic Polyneuropathy (FAP) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 21, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists and collaborators will present pre-clinical and clinical data with patisiran (ALN-TTR02) and ALN-TTRsc – RNAi therapeutics targeting transthyr... 
Printer Friendly Version
03/06/14Alnylam Announces Closing of Previously Announced Acquisition of Merck’s Sirna Therapeutics Subsidiary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. (“Sirna Therapeutics” or “Sirna”) has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pursuant... 
Printer Friendly Version
03/06/14Alnylam to Webcast Presentation at Barclays Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 10:45 a.m. ET at the Loews Miami Hotel in Miami, Florida. A live audio webcast of the presentation will be available on the Investors section of the company’s website, ww... 
Printer Friendly Version
02/27/14Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced alliance with Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) has closed, following the expiration of the Hart-Scott-Rodino waiting period. The two companies formed the collaboration for the development and commercialization of RNAi therapeutics as genetic medici... 
Printer Friendly Version
02/25/14Alnylam to Webcast Presentation at Cowen and Company 34th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 11:20 a.m. ET at The Boston Marriott Copley Place in Boston. A live audio webcast of the presentation will be available on the Investors section of t... 
Printer Friendly Version
02/13/14Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities
– Announced Major Business Transactions Including Transformational Alliance with Genzyme for RNAi Therapeutics as Genetic Medicines and Acquisition of Merck RNAi Assets and Sirna Therapeutics Subsidiary – – Initiated APOLLO Phase 3 Study with Patisiran (ALN-TTR02) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR) in Patients with Familial Amyloidotic Polyneuropathy (FAP) – – Initiated Phase 2 Study with ALN-TTRsc in ATT... 
Printer Friendly Version
02/06/14Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2013 on Thursday, February 13, 2014, after the U.S. financial markets close. Management will provide an update on the company, discuss fourth quarter and year-end 2013 results, and discuss expectations fo... 
Printer Friendly Version
02/04/14Alnylam to Webcast Presentation at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:30 p.m. ET at the Waldorf Astoria in New York City. In addition, Alnylam management will present a company overview at the 2014 Leerink Global Healthca... 
Printer Friendly Version
01/22/14Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
- Company Expects to Present Initial Data from Phase 1 Study in Late 2014- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD). ALN-AT3 has demonstra... 
Printer Friendly Version
01/13/14Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases
- Genzyme to Obtain Significant Global Rights to Alnylam’s Pipeline - - Alnylam Retains Most Product Rights in North America and Western Europe - - Genzyme Becomes Major Alnylam Shareholder through $700 Million Equity Investment - PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2014-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced today that the... 
Printer Friendly Version
01/13/14Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
- New Collaboration Expected to Accelerate and Expand Global Product Value for RNAi Therapeutic Genetic Medicine Pipeline, Including “Alnylam 5x15” Programs - - Alnylam Retains Broad Product Rights in North America and Western Europe and Genzyme Obtains Rights to Access Alnylam’s Genetic Medicines Pipeline in the Rest of World and Receives Co-Development, Co-Commercialization Rights or Global Rights to 3 Programs - - Genzyme Become... 
Printer Friendly Version
01/12/14Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck
– Strategic Transaction Positions RNAi Assets for Future Advancement through Alnylam’s Commitment to RNAi Therapeutics – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 12, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. (“Sirna Therapeutics”), comprising intellectual property and RNAi assets including pre-clinical therapeutic ... 
Printer Friendly Version
01/10/14Alnylam Provides Key 2014 Goals for RNAi Therapeutics Pipeline
- Expects to Exceed “Alnylam 5x15” Guidance; Now Plans to Have 6 to 7 Programs in Clinical Development by End of 2015, Including at Least 2 in Phase 3 and 5 to 6 with Human Proof-of-Concept Data - - Focused on Enrolling Patients in APOLLO Phase 3 with Patisiran (ALN-TTR02) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR) in Patients with Familial Amyloidotic Polyneuropathy (FAP), with Initial Data from Phase 2 Open-Label Exten... 
Printer Friendly Version
01/06/14Alnylam to Webcast Presentation at 32nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 11:30 a.m. PT (2:30 p.m. ET) at the Westin St. Francis Hotel in San Francisco, Calif. This presentation will include a review of the company’s goals and guidance. ... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.